Dana-Farber Cancer Institute: clinical-trial pipeline
Dana-Farber Cancer Institute is the sponsor of 831 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 233 are not yet finished and 5 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 332 |
| Not applicable | 284 |
| Phase 1 | 137 |
| Phase 1/2 | 47 |
| Phase 3 | 15 |
| Early phase 1 | 12 |
| Phase 2/3 | 2 |
| Phase 4 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 470 |
| Active, not recruiting | 111 |
| Recruiting | 107 |
| Terminated | 89 |
| Withdrawn or not authorised | 31 |
| Not yet recruiting | 15 |
| Unknown | 6 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 736 |
| Nephrology and urology | 85 |
| Gastroenterology and liver | 52 |
| Women's health and obstetrics | 50 |
| Rare and genetic diseases | 44 |
| Haematology | 29 |
| Musculoskeletal | 21 |
| Metabolic and endocrine (diabetes, obesity) | 19 |
| Dermatology | 17 |
| Psychiatry and mental health | 16 |
| Neurology | 12 |
| Respiratory | 11 |
Countries
| Country | Trials |
|---|---|
| United States | 808 |
| Canada | 9 |
| Rwanda | 2 |
| Germany | 1 |
| Iran | 1 |
| Puerto Rico | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-29 | New trial posted | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL |
| 2026-09-21 | New trial posted | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial |
| 2026-09-17 | New trial posted | Healing Gardens: Leveraging Serious Games to Deliver Accessible Pain-CBT and Pharmacologi… |
| 2026-09-15 | New trial posted | Bladder Preservation or Cystectomy for MIBC |
| 2026-08-31 | New trial posted | Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Re… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07227584 | ALL Backbone in AYAs | Phase 2 | Recruiting | United States |
| NCT07305740 | On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety | Not applicable | Recruiting | United States |
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Phase 1 | Active, not recruiting | United States |
| NCT07232043 | ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs | Not applicable | Recruiting | United States |
| NCT06117709 | Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing | Not applicable | Recruiting | United States |
| NCT06565052 | The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Under… | Not applicable | Recruiting | United States |
| NCT07482384 | Supporting Health Including Endocrine Treatment for Long Duration | Not applicable | Recruiting | United States |
| NCT06152809 | CIML NK Cells With Venetoclax for AML | Phase 1 | Recruiting | United States |
| NCT03716180 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | Phase 1 | Active, not recruiting | United States |
| NCT05726370 | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | Phase 2 | Recruiting | United States |
| NCT04417062 | Olaparib With Ceralasertib in Recurrent Osteosarcoma | Phase 2 | Active, not recruiting | United States |
| NCT02981940 | A Study of Abemaciclib in Recurrent Glioblastoma | Phase 2 | Active, not recruiting | United States |
| NCT01516190 | The Preoperative Health & Body Study | Not applicable | Active, not recruiting | United States |
| NCT05265429 | Biology of Young Lung Cancer Study: The YOUNG LUNG Study | Not applicable | Recruiting | United States |
| NCT06907797 | Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing | Not applicable | Recruiting | United States |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | Phase 1/2 | Active, not recruiting | United States |
| NCT03818087 | Elevate! : An Elderly Breast Cancer Cohort Study | Not applicable | Active, not recruiting | United States |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | Phase 2 | Recruiting | United States |
| NCT00548236 | The Active After Cancer Trial (AACT) | Not applicable | Active, not recruiting | United States |
| NCT02747888 | Hereditary Risk Factors for Thyroid Cancer | Not applicable | Recruiting | United States |
| NCT03319901 | Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL | Phase 1/2 | Active, not recruiting | United States |
| NCT07735624 | RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer | Phase 2 | Recruiting | United States |
| NCT04630496 | Geriatric Thoracic Surgery Ambulation Challenge | Not applicable | Recruiting | United States |
| NCT03580928 | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL | Phase 2 | Active, not recruiting | United States |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | Phase 1/2 | Recruiting | United States |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Dana-Farber Cancer Institute clinical trials: 233 open, 17 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/dana-farber-cancer-institute/, data as of 2026-10-25.